Akkermansia muciniphila, a key player in the gut microbiome, has emerged as a significant influencer of GLP-1, a hormone with profound implications for metabolic health. Learn from Colleen Cutcliffe, PhD, CEO and Co-founder of Pendulum Therapeutics about the latest research uncovering the impact of A.muciniphila, C.butyricum, B.infantis and other novel strains on GLP-1 signaling, satiety, cravings, and probiotic avenues for metabolic disorders.

This webinar is sponsored by Pendulum Therapeutics. There is no CME associated with this webinar.